Quantum Biopharma is partnering with researchers at Massachusetts General Hospital in Boston on a clinical study to test a positron emission tomography (PET) tracer for monitoring changes in ...

Investigators assessed silmitasertib monotherapy in patients who had failed first-line hedgehog pathway inhibitors, with 27.3% also failing second-line PD-1 inhibitors such as cemiplimab (Libtayo) or ...

You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab (Keytruda). Atezolizumab (Tecentriq) and durvalumab (Imfinzi) may also be given to treat certain types of NSCLC with a ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Regeneron's main product is Duxipent, an autoimmune disease drug. It sells Libtayo, a cancer drug that recently got approved for a new medical indication. Both drugs are sold through a partnership ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid tumors. Recent updates include ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...